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Abstract :  14 
 15 
Extracellular vesicles are a heterogeneous group of cell-derived membranous 16 
structures that comprises exosomes and microvesicles, which originate from 17 
the endosomal system or are shed from the plasma membrane, respectively. 18 
They are present in biological fluids and are involved in multiple physiological 19 
and pathological processes. Extracellular vesicles are now considered as an 20 
additional mechanism for intercellular communication allowing cells to 21 
exchange proteins, lipids and the genetic material. Knowledge of the cellular 22 
processes that govern extracellular vesicle biology is essential to shed light on 23 
physiological and pathological functions of these vesicles as well as on clinical 24 
applications involving their use and/or analysis. Yet, many unknowns still 25 
remain in this expanding field related to their origin, biogenesis, secretion, 26 
targeting and fate. 27 
 28 
 29 
 30 
 31 
 32 
 33 
[H1] Introduction  34 
 2 
 35 
Apart from the release of secretory vesicles by specialized cells, which carry, 36 
for example, hormones or neurotransmitters, all cells are capable of secreting 37 
different types of membrane vesicles, known as extracellular vesicles, and 38 
this process is conserved throughout evolution from bacteria to humans and 39 
plants1 2,3. Secretion of extracellular vesicles has been initially described as 40 
means of eliminating obsolete compounds4 from the cell. However, now we 41 
know that extracellular vesicles are more than waste carriers, and the main 42 
interest in the field is now focused on their capacity to exchange components 43 
between cells — varying from nucleic acids to lipids and proteins — and to act 44 
as signalling vehicles in normal cell homeostatic processes or as a 45 
consequence of pathological developments5,6,7. 46 
 47 
Even though one generic term — extracellular vesicles – is currently in use to 48 
refer to all these secreted membrane vesicles, they are in fact highly 49 
heterogeneous (Fig. 1), which has largely hampered characterization and 50 
manipulation of their properties and functions. Insights into the biogenesis of 51 
secreted vesicles was provided by transmission and immuno-electron 52 
microscopy, and by biochemical means 8-10 . Based on the current knowledge 53 
of their biogenesis, extracellular vesicles can be broadly divided into two main 54 
categories: exosomes and microvesicles (Fig 1a). 55 
 56 
The term exosome (which should not be confused with the exosome complex, 57 
which is involved in RNA degradation11 ) was initially used to name vesicles of 58 
an unknown origin released from a variety of cultured cells and carrying 5’-59 
nucleotidase activity12. Subsequently, the term exosomes was adopted to 60 
refer to membrane vesicles (30-100 nm in diameter) released by reticulocytes 61 
[G] during differentiation4. In essence, exosomes are intraluminal vesicles 62 
(ILVs) formed by the inward budding of endosomal membrane during 63 
maturation of multivesicular endosomes (MVEs) — which are intermediates 64 
within the endosomal system — and secreted upon fusion of MVEs with the 65 
cell surface13,14 (Fig 1a-c). In the mid 1990’s exosomes were reported to be 66 
secreted by B lymphocytes 15 and dendritic cells16 with potential functions 67 
related to immune regulation, and considered for use as vehicles in anti-68 
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tumoral immune responses. Exosome secretion is now largely extended to 69 
many different cell types and their implications in intercellular communication 70 
in normal and pathological states are now well documented5. 71 
 72 
Microvesicles, formerly called “platelet dust”, were described as subcellular 73 
material originating from platelets in normal plasma and serum17. Later, 74 
ectocytosis, a process allowing the release of plasma membrane vesicles, 75 
was described in stimulated neutrophils18. Although microvesicles were mainly 76 
studied for their role in blood coagulation19,20, more recently they were 77 
reported to have a role in cell–cell communication in different cell types, 78 
including cancer cells21 where they are generally called oncosomes. 79 
Microvesicles range in size from 50-1000 nm in diameter, but can be even 80 
larger (up to 10µm) in the case of oncosomes. They are generated by the 81 
outward budding and fission of the plasma membrane and the subsequent 82 
release of vesicles into the extracellular space 22 (Fig 1a-c).  83 
 84 
There is now evidence that each cell type tunes extracellular vesicle 85 
biogenesis depending on its physiological state, and to release extracellular 86 
vesicles with particular lipid, protein and nucleic acid compositions5 (Fig. 1d). 87 
Because most published reports of extracellular vesicles have focused on 88 
their potential functions rather their origins, it is still unclear which sub-species 89 
of vesicles is responsible for any given effect. The current available protocols 90 
to recover extracellular vesicles from cell culture supernatants or liquid 91 
biopsies result in a heterogeneous population of vesicles of unknown origin 23. 92 
Moreover, the diversity of isolated extracellular vesicle populations is further 93 
expanded by the inclusion of additional structures into the pool of extracellular 94 
vesicles, such as the apoptotic bodies, migrasomes, which transport 95 
multivesicular cytoplasmic contents during cell migration24 or arrestin domain-96 
containing protein 1-mediated microvesicles (ARMMS)25, which are largely 97 
uniform, ~50 nm in diameter, microvesicles that have been shown to bud 98 
directly from the plasma membrane in a manner resembling the budding of 99 
viruses and dependent on arrestin domain-containing protein 1 (ARRDC1) 100 
and on endosomal sorting complex required for transport (ESCRT) proteins 101 
(similarly to a sub-population of exosomes; see also below). 102 
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 103 
 104 
The overlapping range of size, similar morphology and variable composition 105 
challenge current attempts to devise a more precise nomenclature of 106 
extracellular vesicles26 27. Nevertheless, novel isolation and characterization 107 
methods are being developed to allow a more thorough description of 108 
respective functions of the different types of extracellular vesicles and to 109 
establish a suitable classification and terminology. Moreover, to validate 110 
respective roles of exosomes and microvesicles, efforts are being made to 111 
uncover mechanisms underlying the targeting of the different cargoes that 112 
these vesicles transport to the site of extracellular vesicle biogenesis, the 113 
generation and secretion of vesicles, and their fate in target cells. Here, we 114 
review current knowledge and delineate unknown aspects of the essential 115 
cellular processes that govern the biology of mammalian extracellular 116 
vesicles, including their potential physiological roles, as well as their relevance 117 
to disease and to clinical applications.  118 
 119 
 120 
[H1] Biogenesis of extracellular vesicles  121 
 122 
Exosomes and microvesicles have different modes of biogenesis (but both 123 
involve membrane trafficking processes): exosomes are generated within the 124 
endosomal system as ILVs and secreted during fusion of MVEs with the cell 125 
surface, whereas microvesicles originate by an outward budding at the 126 
plasma membrane10. This nomenclature is still questionable as extracellular 127 
vesicle biogenesis pathways may differ according to the producing cell type. 128 
For example, T cells generate primarily extracellular vesicles from the cell 129 
surface with characteristics of exosomes, likely exploiting at the plasma 130 
membrane molecular components and mechanisms that are usually 131 
associated with the endosomal biogenesis of ILVs28. This peculiar biogenesis 132 
of exosomes from the plasma membrane might be specific to T cells, which 133 
also use the endosomal machinery for HIV budding at the plasma 134 
membrane29.  135 
 136 
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Even though generation of microvesicles and exosomes occurs at distinct 137 
sites within the cell, common intracellular mechanisms and sorting 138 
machineries [G] are involved in the biogenesis of both entities. In many cases 139 
these shared mechanisms hinder the possibility to distinguish among them5. 140 
Mechanistic details of extracellular vesicle biogenesis have just started to be 141 
uncovered as discussed below. First, cargoes scheduled for secretion within 142 
extracellular vesicles must be targeted to the site of production, either at the 143 
plasma membrane (for microvesicles) or at the limiting membrane of MVE (for 144 
exosomes). Second, cargoes are enriched in the forming vesicles by a 145 
stepwise mechanism of clustering and budding followed by fission and vesicle 146 
release (Fig 2).  147 
 148 
[H3] Cargoes and their targeting to the site of extracellular vesicle 149 
generation. 150 
The nature and abundance of extracellular vesicle cargoes30 (Fig 1d) is cell 151 
type specific and is often influenced by the physiological or pathological state 152 
of the donor cell, the stimuli that modulate their production and release, and 153 
the molecular mechanisms that lead to their biogenesis31. Cargoes are the 154 
first regulators of extracellular vesicle formation. As reported for exosomes, an 155 
ectopic expression of a particular cargo such as, for example the expression 156 
of the major histocompatibility complex [G] (MHC) class II32 promotes MVE 157 
formation with a consequent release of extracellular vesicles, likely by 158 
recruiting sorting machineries that will promote MVE and ILV generation32,33.  159 
 160 
Exosomal membrane cargoes reach endosomes from the Golgi apparatus or 161 
are internalized from the plasma membrane before being sorted to ILVs 162 
during endosome maturation34 (Fig 1). Hence cargoes that are preferentially 163 
recycled to the plasma membrane are likely not enriched in exosomes unless 164 
their recycling is impaired, as is the case for the transferrin receptor in 165 
reticulocytes35. Therefore, impairment or depletion of regulators of endosomal 166 
recycling and retrograde transport from endosomes to the Golgi might 167 
generally affect the targeting of some cargoes to extracellular vesicles. In this 168 
context, syntenin [G] protein, by acting both in the recycling36 and in the 169 
sorting of syndecan [G] in MVEs37 for exosome biogenesis, appears as a 170 
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potential regulator of the crossroad between endocytic recycling and 171 
endosomal targeting of potential exosomal cargoes. 172 
 173 
Modulation of endocytosis or recycling of cargoes to the plasma membrane 174 
would also impinge on their targeting at the site of microvesicle biogenesis. 175 
For example, the small GTPase ADP-ribosylation factor 6 (ARF6) was 176 
identified as a regulator of selective recruitment of proteins, including β1 177 
integrin receptors, MHC class I molecules, membrane type 1-matrix 178 
metalloproteinase 1 (MT1-MMP) and the vesicular soluble N-ethylmaleimide-179 
sensitive factor attachment protein receptor (v-SNARE) VAMP3 into tumour-180 
derived microvesicles38,39. In addition to ARF6-regulated endosomal 181 
trafficking, VAMP3 mediates the trafficking and incorporation of MT1-MMP 182 
into tumor-derived microvesicles in a CD9-dependent manner. This suggests 183 
that VAMP3- and ARF6-positive recycling endosomes are a site of MT1-MMP 184 
recycling to the cell surface and trafficking to microvesicles. Such crosstalk 185 
between recycling and microvesicle biogenesis is also illustrated by studies 186 
reporting that the small GTPase Rab22a co-localizes with budding 187 
microvesicles and mediates packaging and loading of cargo proteins in 188 
hypoxic breast cancer cells40.  189 
 190 
 191 
[H3] Machineries involved in the biogenesis of exosomes. 192 
Exosomes are generated as ILVs within the lumen of endosomes during their 193 
maturation into MVEs, a process that involves particular sorting machineries. 194 
These machineries first segregate cargoes on microdomains of the limiting 195 
membrane of MVEs with consequent inward budding and fission of small 196 
membrane vesicles containing sequestered cytosol (Fig 2).  197 
 198 
The discovery of the ESCRT machinery as a driver of membrane shaping and 199 
scission was the first breakthrough into uncovering the mechanisms involved 200 
in the formation of MVEs and ILVs41. ESCRT acts in a stepwise manner 201 
where ESCRT-0 and ESCRT-I subunits cluster ubiquitinated transmembrane 202 
cargoes on microdomains of the limiting membrane of MVEs and recruit, via 203 
ESCRT-II, the ESCRT-III subcomplexes that perform budding and fission of 204 
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this microdomain (Fig 2). Accordingly, Hrs (ESCRT-0) appears to be required 205 
for exosome formation and/or secretion by dendritic cells42.  206 
 207 
The role of the ESCRT machinery in ILV biogenesis and the presence of 208 
some ESCRT subunits in exosomes opened an avenue to understand and 209 
modulate the formation of exosomes through manipulation of the ESCRT 210 
components. A medium-throughput RNA interference screen targeting 23 211 
different components of ESCRT machinery and associated proteins highlights 212 
has revealed various roles for selected members of this family in exosomes 213 
generation. Their inactivation impacts either the efficiency of secretion or the 214 
composition of the secreted vesicles indicating that some ESCRT 215 
components could act selectively on MVE and ILV subpopulations fated for 216 
secretion as exosomes43. The canonical ESCRT pathway can be intersected 217 
by syntenin and ALIX (ALG-2 interacting protein X; an ESCRT accessory 218 
protein; also known as PDCD6-interacting protein), which bridge cargoes and 219 
the ESCRT-III subunit vacuolar protein sorting-associated protein 32 (VPS32; 220 
also known as CHMP4)37.  221 
 222 
Exosomes can be also formed in an ESCRT-independent manner, which was 223 
revealed by studies showing that MVEs, featuring ILVs loaded with CD63 are 224 
still formed upon depletion of components of the four ESCRT complexes44. 225 
The first ESCRT-independent mechanism of exosome biogenesis was shown 226 
to require generation of ceramide [G] by neutral type II sphingomyelinase that 227 
hydrolyzes sphingomyelin [G] to ceramide45. Ceramide may then allow 228 
generation of membrane subdomains46, which impose spontaneous negative 229 
curvature on the membranes. Alternatively, ceramide could be metabolized to 230 
sphingosine 1-phosphate to activate Gi-protein coupled sphingosine 1-231 
phosphate receptor that appears essential for cargo sorting into exosomal 232 
ILVs47 (Fig 2). In addition, proteins of the tetraspanin family [G], have been 233 
shown to regulate the ESCRT-independent endosomal sorting. One of these 234 
proteins is CD63, which is particularly enriched on the surface of exosomes 235 
and has been shown to be involved in endosomal sorting in melanocytes48,49 , 236 
in cargo (apolipoprotein E) targeting to exosomes secreted by melanoma 237 
cells50 and in the biogenesis of exosomes in fibroblasts from down syndrome 238 
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patients51. Tetraspanins CD81, CD82 and CD9 are also directly involved in 239 
the sorting of various cargo to exosomes52,53. Mechanistically, these proteins 240 
form clusters and dynamic membrane platforms with other testraspanins and 241 
with different transmembrane and cytosolic proteins54 likely acting in the 242 
formation of the microdomains that will bud. Moreover, recent structural 243 
analysis of the tetraspanin CD81 revealed a cone-like structure with an 244 
intramembrane cavity that can accommodate cholesterol and that is likely 245 
shared by other tetraspanins. Clustering of several cone-shaped tetraspanins 246 
could then induce inward budding of the microdomain in which they are 247 
enriched55 (Fig 2). But tetraspanins also regulate the intracellular routing of 248 
cargoes towards MVEs, such as integrins56, which indicates that impairment 249 
of their function may affect different steps of exosome generation. Thus, it 250 
seems that both ESCRT-dependent and -independent mechanisms operate in 251 
exosome biogenesis, and their contribution may vary depending on the 252 
cargoes, which recruit them, and the cell type. 253 
 254 
As mentioned above, sorting of transmembrane cargoes into extracellular 255 
vesicles is largely dependent on endosomal sorting machineries. However, 256 
additional mechanisms contribute to the targeting of selective soluble or 257 
membrane associated cargoes to exosomes. For example, the sequestration 258 
of cytosolic proteins into ILVs can results from co-sorting with other proteins, 259 
such as chaperones heat shock protein 70 (HSP70) and heat shock cognate 260 
70 (HSC70), which are found in exosomes derived from most cell types57,58. 261 
Membrane cargoes, such as GlycosylPhosphatidyInostol (GPI)-anchored 262 
proteins [G] are present in exosomes likely because of their affinity for lipid 263 
domains and lipid rafts [G] that could be directly involved in ILV generation 264 
through their effects on biophysical properties of membranes59. It has also 265 
been proposed that some cytosolic proteins, modified by ubiquitylation60 or 266 
farnesylation61 are segregated in ILVs and in exosomes but the underlying 267 
mechanisms for their enrichment in these compartments are still lacking. 268 
Apart from proteins, extracellular vesicles also carry nucleic acids, including 269 
RNAs (mRNAs and non-coding RNAs including micro RNAs (miRNAs)62,63 270 
and DNA sequences64,65. Interestingly, miRNAs have been shown to be 271 
differentially sorted to exosomes, depending on their sequence (presence of 272 
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specific motifs)66, which indicates that incorporation of nucleic acids into 273 
exosomes is regulated . However, the relative contributions of passive and 274 
active loading of RNAs into extracellular vesicles remain unclear67. The 275 
mechanisms involved in targeting nucleic acids to exosomes are so far 276 
elusive. Different machineries have been proposed to perform specific nucleic 277 
acid sorting, including the ESCRT-II subcomplex that could act as an RNA 278 
binding complex68, the tetraspanin-enriched microdomains that could 279 
sequester many RNA-binding proteins in the membrane subdomains69 or the 280 
miRNA-induced silencing complex (miRISC) and protein argounaute 2 281 
(AGO2), which mediate RNA silencing processes70. New regulators of miRNA 282 
sorting into exosomes have also recently been described and include the 283 
KRAS–MEK signalling pathway [G] acting through AGO2 71, Major Vault 284 
protein [G] 72 or Y-box protein 1 [G] 73.  285 
 286 
In sum, exosome biogenesis is certainly complex and varies depending on the 287 
cargo and on the cell type and can be influenced by other signals and 288 
pathological stimuli that the cell can receive. The balance of these pathways 289 
leading to changes in the compositional repertoire of exosomes also changes 290 
over the course of the differentiation process as reported for reticulocytes74, or 291 
during cell maturation as shown for dendritic cells75. Accordingly, most cells 292 
host subpopulations of MVEs distinguished by different lipid and protein 293 
compositions and morphology52,76. In this context, different sorting 294 
mechanisms can act on the same endosomal compartment49 or different 295 
machineries can be used for targeting the same cargo (for example MHCII, 296 
which can be targeted to MVEs by both ESCRT-dependent and independent 297 
mechanisms)52,77, or on different maturation products of the cargo (as is the 298 
case for melanocyte protein PMEL for which its luminal domain, which is 299 
generated by proteolysis, is sorted by ESCRT-independent mechanisms, 300 
whereas ESCRT-dependent mechanism is involved in targeting the 301 
transmembrane domain of PMEL)49. Therefore several mechanisms could 302 
concomitantly or sequentially act on forming MVEs, thereby allowing the 303 
sorting of diverse cargoes at different stages of maturation of the MVE78; 304 
alternatively or concomitantly, distinct subpopulations of MVEs may exist and 305 
may be targeted by different machineries5,49 (Fig 3). Overall, this data support 306 
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a model, whereby the biogenesis of exosomes involves several distinct 307 
mechanisms for the preferential recruitment of cargoes likely generating 308 
heterogeneous populations of ILVs and exosomes within common or distinct 309 
subpopulations of MVE5,6.Overall, as major regulators of the composition of 310 
exosomes, endosomal sorting machineries appear as main determinants of 311 
their functional properties. Therefore, agents or activities affecting early 312 
endosomal sorting machineries and their dynamics should be considered 313 
when investigating exosome generation and for their manipulation. 314 
 315 
 316 
 317 
[H3] Machineries involved in the biogenesis of microvesicles. 318 
Whereas blebbing from the plasma during apoptosis has long been known to 319 
produce microvesicles in the form of apoptotic bodies79, the release of 320 
microvesicles from the plasma membrane of healthy cells and the 321 
mechanisms involved in this secretion have only started to emerge recently. 322 
This biogenesis requires several molecular rearrangements within the plasma 323 
membrane, including changes in lipid components and protein composition, 324 
and in Ca2+ levels31. Ca2+-dependent enzymatic machineries including 325 
aminophospholipid translocases [G] (flippases and floppases), scramblases 326 
[G] and calpain [G] drive rearrangements in the asymmetry of membrane 327 
phospholipids (exposition of phosphatidylserine from the inner leaflet to the 328 
cell surface), which causes physical bending of the membrane and 329 
restructuring of the underlying actin cytoskeleton, which favour membrane 330 
budding and formation of microvesicles21,80 (Fig 2). A genetic defect in the 331 
activity of the lipid scramblase suppresses the exposure of phosphatidylserine 332 
on blood platelets, and the production of procoagulant-containing 333 
microvesicles80. However, even when the membrane lipid asymmetry is 334 
maintained, microvesicle biogenesis might proceed81,82. These observations 335 
suggest that other lipids, and the domains they form, contribute to 336 
microvesicle biogenesis. One important lipid component is cholesterol, which 337 
is abundant in microvesicles and pharmacological depletion of which impairs 338 
their generation in activated neutrophils83.  339 
 340 
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In addition to lipids, cytoskeletal elements and their regulators are certainly 341 
required for microvesicle biogenesis. The activity of Rho family of small 342 
GTPases [G] and of the Rho-associated protein kinase (ROCK), which are 343 
important regulators of actin dynamics, induce microvesicle biogenesis in 344 
different populations of tumor cells84. As another example, in the enterocyte 345 
brush border [G] , myosin 1a distributed along the microvillar tips exerts plus 346 
end-directed force on the apical membrane, leading to the formation and 347 
release of gut microvesicles85. 348 
 349 
The biogenesis of tumor-derived microvesicles (oncosomes) is also tightly 350 
associated with metabolic changes, the so-called Warburg effect [G] 86. In 351 
breast cancer cells, elevated glutaminase activity is dependent on Rho 352 
GTPases87, and inhibition of its activity blocks microvesicle biogenesis. This 353 
suggest that formation and loading of microvesicles is linked to their metabolic 354 
capability and to the Rho-GTPase signalling pathway, even beyond its role in 355 
actomyosin regulation. 356 
 357 
As for cargo targeting to exosomes, lipids and other membrane associated 358 
cargoes are localized to sites of microvesicle budding through their affinity for 359 
lipid rafts or as is the case for oligomeric cytoplasmic proteins, by their 360 
anchoring to plasma membrane lipids88,89 — two mechanisms that are 361 
strikingly analogous to the budding of HIV and other retroviruses. Cytosolic 362 
components fated for secretion into microvesicles require their binding to the 363 
inner leaflet of the plasma membrane. This association is dependent on their 364 
respective plasma membrane anchors (palmitoylation, prenylation, 365 
myristoylation) and the establishment of high-order complexes, that 366 
concentrates them to the small membrane domains from which forming 367 
microvesicles will bud88,89. It is still unclear how nucleic acids, which are 368 
generally found in microvesicles, are targeted to cell surface. One possible 369 
mechanism revealed from studies of cancer cells suggests the involvement of 370 
conserved zipcode RNA sequence motifs [G] in the 3’ untranslated regions in 371 
mRNA targeting into microvesicles90, but the details of this process remain to 372 
be discovered. 373 
 374 
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[H1] The release of extracellular vesicles 375 
Once formed, microvesicles pinch off from the plasma membrane whereas 376 
exosome secretion requires the transport and apposition of MVEs to the 377 
plasma membrane to fuse with and release ILVs (as exosomes) into the 378 
extracellular milieu. The different intracellular events leading to their secretion 379 
are likely to impose a time difference between generation and release of both 380 
types of extracellular vesicles. Release of microvesicles would be likely faster 381 
as cargoes only need to remain at the plasma membrane to be targeted to 382 
microvesicles and their subsequent release would directly follow their 383 
generation and fission. On the contrary, release of exosomes requires 384 
additional steps to sort cargoes to MVEs, then to ILVs and extrasteps to target 385 
MVEs to the plasma membrane and to prime them for secretion. Such 386 
difference could be relevant from a functional point of view as it imposes 387 
additional regulatory “checkpoints” for the secretion of exosomes as 388 
compared to microvesicles. Whereas in some cases, such as embryonic 389 
development, cell differentiation and in general during maintenance of 390 
physiological homeostasis the release could be constitutive, this process may 391 
also be subjected to further modulation by the physiological state of the cell 392 
and the requirement for the supply of key structural components or other 393 
mechanisms that would act as triggers for secretion such as the generation of 394 
immunological synapse [G] 52,91. As the release of microvesicles is likely the 395 
direct consequence of their generation and fission, in the next sections we 396 
focus on exosome release and only summarize the few studies on potential 397 
mechanisms that could be involved in microvesicle secretion. 398 
 399 
[H3] Avoiding MVE degradation. 400 
MVEs are primarily destined to fuse with lysosomes for degradation. 401 
However, mechanisms preventing their degradation and allowing MVE 402 
secretion exist, thereby enabling exosome secretion (Fig 3 and 4). The 403 
regulation of the balance between degradative and secretory capacity of 404 
MVEs remains largely unexplored, but the setting of this balance undoubtedly 405 
impacts on cell function. For example, lysosomal degradation defects that 406 
promote exosome secretion have been shown to enable efficient elimination 407 
of unwanted and/or defective proteins such as amyloids in the context of 408 
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neurodegenerative diseases92,93. The impairment of lysosomal activity by 409 
inhibiting the endosomal proton pump V-ATPase also leads to an increase of 410 
exosome release94,95, and, for example, has been shown to trigger apical 411 
secretion of Hedgehog [G] -related peptides through a multivesicular 412 
compartment in Caenorhabditis elegans96. 413 
 414 
Some insights into how the balance between targeting MVEs for secretion 415 
and degradation is established have recently emerged. A first level of 416 
regulation of this balance is likely imposed by the sorting machineries at 417 
MVEs. While the different components of ESCRT machinery have various 418 
effect on exosomes secretion23 and generally associated with degradative 419 
MVE, the syndecan–syntenin–ALIX pathway seems to be restricted so far to 420 
exosome secretion37. On the same line, MHCII is targeted to MVEs fated for 421 
lysosomal degradation through ubiquitination (likely recruiting ESCRT 422 
machinery) while ubiquitin- (and likely ESCRT-) independent mechanisms 423 
target MHC II to MVEs fated for secretion52,77. The mechanisms underlying 424 
this balance are still unclear but involve components of various sorting 425 
machineries such as ESCRT-I component tumour susceptibility gene 101 426 
protein (TSG101), whose ISGylation [G] favours lysosomal degradation (and 427 
thereby impairment of exosome secretion)94, or the tetraspanin 697, 428 
overexpression of which slows down lysosomal degradation likely by 429 
recruiting sorting machinery that involves the syntenin pathway. These 430 
findings are in accordance with the involvement of ESCRT-independent 431 
machineries in the generation of MVEs fated for exosome secretion but not for 432 
lysosome degradation49,52,98.  433 
 434 
A similar balance exists between exosome secretion and macroautophagy — 435 
the process that drives degradation of superfluous or damaged cellular 436 
components in the lysosome to maintain cellular homeostasis and that 437 
promotes energy conservation under stress. More specifically, the fusion of 438 
MVEs with autophagosome would promote their degradation and prevent 439 
exosome secretion99 (Fig 4). In this context, it has been shown that the prion 440 
protein (PrP) can promote exosome secretion by inhibiting autophagosome 441 
formation and it does so by interacting with caveolin [G] and modulating its 442 
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inhibitory effect on autophagosome formation100. Of interest, chemical 443 
inhibition of autophagy increases the recovery of autophagosome-associated 444 
proteins in the isolated exosomal pellet but not of exosome-enriched 445 
proteins101. This suggests that the capacity of MVEs to secrete exosomes is 446 
counter-balanced by their fusion with the autophagosome. Yet, 447 
autophagosomes and MVEs can both secrete their content but the molecular 448 
mechanisms regulating these secretory pathways are likely distinct.  449 
 450 
[H3] Transport of MVEs.  451 
As discussed above, MVEs fuse either with lysosomes for degradation of their 452 
content or with the plasma membrane. In both cases a two-step process 453 
involving their transport (motility) and fusion is required, but the effectors 454 
involved in targeting MVEs to the lysosomes or to the plasma membrane are 455 
certainly distinct.  456 
 457 
In general, intracellular transport involves the association of organelles with 458 
the cell cytoskeleton (actin, microtubules), associated molecular motors 459 
(dynein, kinesins, myosins) and molecular switches (Small GTPases)102 ,103.  460 
Exosome secretion is provided by the oriented secretion of these vesicles 461 
towards the immunological synapse between antigen-presenting cells and T 462 
cells during antigen presentation52,104. This implies that at least in the context 463 
of immunological synapse MVEs follow the network of microtubules oriented 464 
by the microtubule organizing centre (typically the centrosome)91 (Fig 4). The 465 
molecular motors involved in this process remain to be determined but 466 
certainly counterbalance those that regulate transport of MVEs towards 467 
lysosomes. Targeting to lysosomes occurs by a retrograde transport on 468 
microtubules (towards microtubule minus ends), and Rab-GTPase Rab7 and 469 
its associated proteins promote the recruitment of the retrograde molecular 470 
motor dynein that targets MVE to lysosomes105. Interestingly, Rab7 is also 471 
mandatory for the release of exosomes37. These dual effect on exosome 472 
secretion seems to rely on the ubiquitylation status of Rab7, which has been 473 
shown to promote the recruitment of the machinery involved in lysosomal 474 
targeting of MVEs at the expense of exosome secretion106. Curiously, in 475 
endosomes the recruitment of Rab7 leading to lysosomal targeting is 476 
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stimulated by cholesterol at their limiting membrane, whereas MVE-containing 477 
ILVs enriched in cholesterol have been shown to undergo preferential 478 
secretion as exosomes107. Thus, dynamic changes in the composition of the 479 
limiting membrane of MVEs, through incorporation of specific lipids and 480 
proteins into ILVs, would likely regulate the fate of MVEs towards degradation 481 
or secretion. 482 
 483 
Rab27a and Rab27b32 and their respective effectors, synaptotagmin-like 484 
protein 4 and exophilin 5, are also essential for exosome secretion. Rab27b 485 
regulates the motility of MVEs towards the plasma membrane, and both 486 
Rab27 isoforms act on the step following MVE transport, that is the docking at 487 
the plasma membrane to promote fusion, thereby increasing exosome 488 
secretion. The role of Rab27a in MVE docking involves rearrangement of sub-489 
membrane actin cytoskeleton108, a step that is common to all mechanisms 490 
involving vesicular secretion. Rab27 also controls secretion of secretory 491 
lysosomes so called lysosome related organelles109, which suggests that 492 
MVEs capable of exosome secretion may be considered as a specialized 493 
compartment rather than a simple MVE subtype. Of note, Rab27 isoforms are 494 
not constitutively expressed in all cell types, which implies that each cell type 495 
may adapt its own secretory machineries for exosome secretion. This is 496 
illustrated by reported involvement of additional Rabs and their effectors, such 497 
as Rab11 and Rab35 effector110,111 in the direct regulation or the potential 498 
priming of MVE secretion.  499 
 500 
[H3] Fusion of MVEs with the plasma membrane.  501 
The final step of exosome secretion requires the fusion of MVEs with the 502 
plasma membrane to release ILVs as exosomes (Fig 4), a process likely 503 
mediated by SNARE proteins [G] and synaptotagmin family [G] members112. 504 
A SNARE complex known to be implicated in the exocytosis of conventional 505 
lysosomes consists of VAMP7 on the lysosomes, syntaxin 7 on the plasma 506 
membrane and the lysosomal regulatory protein synaptotagmin 7113. This 507 
complex is involved in exosome secretion in some cells (human leukemia 508 
K562 cell line)114 but not in others (MDCK cells)115. The process of exosome 509 
secretion has been demonstrated in several cell types to be regulated by Ca2+ 510 
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116-118, which may have a role in the activation of the SNARE complexes. The 511 
implication of SNAP23 — a SNARE shown to regulate lysosome-related 512 
organelles secretion in mastocytes119 — also in exosome secretion120, 513 
strengthens the notion that MVEs are indeed specialized secretory organelles. 514 
Additional SNARE proteins involved in exosome secretion such as YkT6 121 in 515 
Drosophila, SYX-5 in C. elegans 122 and syntaxin 1a 123 in mammals reflect 516 
again the diversity of regulators that could be involved in exosome secretion, 517 
most likely depending on the organism, the cell type or the MVE subtypes. It 518 
should be noted that most of the studies on the intracellular regulators of 519 
exosome release came from analysis of exosomal pellets isolated from 520 
supernatants from cell cultures treated with inhibitors or interfering RNAs 521 
against potential targets, ignoring the complexity of intracellular pathways that 522 
might be affected in the producing cells by these perturbations. Moreover, the 523 
quantity of extracellular vesicles recovered in the supernatant does not take 524 
into account the fraction of vesicles that remains tethered (not fully released) 525 
at the plasma membrane of the producing cells95 or the fraction of 526 
extracellular vesicles that can be recaptured by the same cell124. A better 527 
understanding of this step certainly requires the development of new tools and 528 
techniques to follow docking and fusion of MVEs with the plasma membrane.  529 
 530 
[H3] Release of microvesicles. 531 
The release of microvesicles requires their fission from the plasma 532 
membrane, a mechanism that is dependent on the interaction of actin and 533 
myosin with a subsequent ATP-dependent contraction85,125. As such, the 534 
activation of small GTP binding proteins including ARF6 and ARF1 leads to 535 
the phosphorylation of the myosin light chain (MLC) and actomyosin 536 
contraction, which allows the vesicles to bud off from the membranes of 537 
cancer cells39 126 127. In HeLa cells another regulator of actin dynamics, Cdc42 538 
has been shown to be involved, but the underlying mechanism is still not 539 
known84. Interestingly, TSG101 and VPS4-ATPase, mostly involved in 540 
exosomes generation as part of the ESCRT machinery, were reported to 541 
participate in the scission and release of ARMMs (subtype of microvesicles 542 
containing ARRDC1)25. Shedding of ESCRT-dependent microvesicles was 543 
also reported in C. elegans embryos upon loss of the conserved flippase P4-544 
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ATPase, TAT-5, which leads to the cytosolic exposure of 545 
phosphatidylethanolamine, an aminophospholipid asymmetrically enriched in 546 
the inner leaflet of the membrane bilayer128. This scenario mirrors the 547 
exposure of phosphatidylserine by lipid translocation, which as discussed 548 
above, can promote membrane bending and microvesicle budding. (Fig 2) 549 
 550 
The involvement of cell signalling pathways in microvesicle release is strongly 551 
supported by reports showing that removal of serum, and therefore growth 552 
factors acting on their respective receptors and downstream effectors, 553 
prevents microvesicle release129. What is known is that a strong microvesicle 554 
release is induced by increased concentration of Ca2+, which by activating 555 
scramblase and calpain leads to a loss of membrane phospholipid asymmetry 556 
and the reorganization of the cytoskeleton (see above) or by the activation of 557 
protein kinase C [G] by phorbol esters130. Release of microvesicles has also 558 
been shown to depend on ATP-mediated activation of P2x7 receptors [G] , 559 
which leads to rearrangements of the cell membrane131,132. Mechanistically, 560 
this process is associated with the translocation of the acidic 561 
sphingomyelinase to the plasma membrane where it generates ceramide, 562 
thereby promoting membrane bending and microvesicle shedding133. The 563 
involvement of acidic rather than neutral sphingomyelinase in microvesicle 564 
release suggests that different members of the sphingomyelinase family 565 
control the biogenesis of exosomes45 (see above) and the release of 566 
microvesicles, but in both cases, these mechanisms would support ESCRT -567 
independent vesicle release. 568 
 569 
[H1] Targeting to recipient cells  570 
Once released into the extracellular space extracellular vesicles can reach 571 
recipient cells and deliver their content to elicit functional responses and 572 
promote phenotypical changes that will impact on their physiological or 573 
pathological status. Extracellular vesicle-mediated intercellular communication 574 
requires docking at the plasma membrane, followed by the activation of 575 
surface receptors and signalling, vesicle internalization (endocytosis) or their 576 
fusion with target cells (Fig 5). The mode of vesicle interaction with the cell 577 
surface and the mechanisms that mediate the transfer of extracellular vesicle 578 
 18 
cargoes are not fully unravelled. These processes are complex and depend 579 
on the origin of extracellular vesicles and on the identity and origin of the 580 
recipient cells, as well as seem to be linked to the downstream effects and 581 
processes instigated by these vesicles134. Current studies have been mostly 582 
focused on investigating membrane interaction and intercellular fate of pools 583 
of exosomes, but despite different content and size, the principles of uptake 584 
and general intercellular trafficking of different sub-populations of extracellular 585 
vesicle are likely to be shared.  586 
 587 
[H3] Binding of extracellular vesicles to their target cells.  588 
Target cell specificity is likely to be determined by specific interactions 589 
between proteins enriched at the surface of extracellular vesicles and 590 
receptors at the plasma membrane of the recipient cells, as for example, in 591 
follicular dendritic cells [G] 135,intestinal epithelial cell136, dendritic cells137, or 592 
neurons 138, and also in liver, lungs or lymph nodes136,139. Of note, the 593 
recipient cells can also be the producing cell itself, leading to autocrine 594 
responses124. 595 
 596 
Several mediators [Au:OK?] OK of these interactions are known and include 597 
tetraspanins, integrins, lipids, lectin [G] or heparan sulfate proteoglycans [G], 598 
and extracellular matrix (ECM) components (Fig 5 inset). The cellular and 599 
molecular basis for the specific targeting to acceptor cells is still unclear, 600 
although some data is available. For example, integrins on extracellular 601 
vesicles can interact with adhesion molecules such as intercellular adhesion 602 
molecules [G] (ICAMs)140 at the surface of recipient cells. In addition, the 603 
interaction of integrins with extracellular matrix proteins, mostly fibronectin 604 
and laminin, has been shown to have important roles in exosome141,142 and 605 
microvesicle 143 binding to recipient cells. In this context, the ECM can act as a 606 
“zipper” between integrins present on extracellular vesicles and target cells. In 607 
vivo, integrin heterodimers may drive extracellular vesicles towards specific 608 
target organs139. One example includes exosomes released by cancer cells, 609 
which can be targeted to specific organs such as lung and liver, to promote 610 
premetastatic niche formation in a manner dependent on their integrin 611 
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composition139. Exosomal tetraspanins could also regulate cell targeting. They 612 
have been shown to interact with integrins144 and to promote exosome 613 
docking and uptake by selected recipient cells145,146. Other molecules such as 614 
heparan sulphate proteoglycan and lectins, both present in extracellular 615 
vesicles and at the plasma membrane, contribute to their docking and/or 616 
attachment of these vesicles to recipient cells (Fig 5). Glypican-1, a cell 617 
surface proteoglycan that bears heparan sulfate, and CD44, a cell-surface 618 
glycoprotein involved in cell–cell interactions, are involved in exosome147 and 619 
microvesicle148 docking, respectively. The lipid composition of extracellular 620 
vesicles can also have an impact on recipient-cell targeting. For example, 621 
phosphatidylserine can recruit specific lipid-binding proteins such as Galectin 622 
5 or Annexin 5140 149,150 that then induce docking of vesicles to the target cell 623 
membrane.  624 
 625 
[H3] Uptake and intracellular fate of extracellular vesicles.  626 
Once they have bound to recipient cells extracellular vesicles may remain at 627 
the plasma membrane 135; 52 or may be internalized by clathrin-mediated or 628 
clathrin-independent endocytosis, such as macropinocytosis [G] and 629 
phagocytosis151-153 as well as through endocytosis via caveolae and lipid 630 
rafts157-159 (Fig 5 ). Of note, certain cell types, such as HeLa cells or EBV-631 
transformed B cell line release clusters of exosomes, as a result of tethering 632 
the vesicles by protein tetherin95. This clustering may affect the way these 633 
vesicles are internalized, favouring phagocytosis or macropinocytosis to 634 
support the engulfment of such large masses or aggregates of extracellular 635 
vesicles151.  636 
 637 
Specific composition of extracellular vesicles will influence their fate. The 638 
presence of Amyloid precursor protein on one exosome subtype from 639 
neuroblastoma cells will specifically target them to neurons contrary to a 640 
CD63 enriched exosome subtype that binds both neurons and glial cells154. 641 
Another example is the presence of syncitin at the surface of exosomes 642 
derived from the trophoblast [G] that promotes their uptake 155, whereas the 643 
presence of a “don’t eat me” signal , such as CD47, at the surface has been 644 
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shown to have a strong inhibitory effect on vesicle phagocytosis by 645 
monocytes 156.  646 
 647 
The fate of extracellular vesicles is also likely related to the presence of 648 
specific structures at the plasma membrane of the target cell. As an illustrative 649 
example, it has been shown that microvesicles derived from microglia [G] 650 
show largely different dynamics of interaction with membranes of microglia 651 
and astrocytes [G] 157. It has also been shown that filopodia [G] drive 652 
extracellular vesicles toward sites of uptake158. The lipid composition of the 653 
plasma membrane of recipient cells such as the presence of lipid raft also 654 
contributes to extracellular vesicle internalization as disruption of lipid rafts by 655 
cholesterol depletion reduces uptake of extracellular vesicles159.  656 
 657 
Following interaction with the plasma membrane of recipients cells157 and after 658 
uptake by different mechanisms, extracellular vesicles follow the endocytic 659 
pathway and reach MVEs, which in most cases, are targeted to the 660 
lysosome160,161. In some cases the internalized vesicles may escape digestion 661 
by back fusion with the limiting membrane of the MVE, thereby releasing their 662 
content into the cytoplasm of the recipient cell162, a process that is still poorly 663 
understood but of prime importance to release intraluminal nucleic acid 664 
structures (Fig 5). The restricted co-localization of trophoblast-derived 665 
exosomes with early but not late endosomal structures also suggests that 666 
some internalized extracellular vesicles could escape lysosomal degradation 667 
by being re-secreted either via the early endocytic recycling pathway or by 668 
fusion of MVEs with the plasma membrane (Fig 5) 155.  669 
 670 
Advances in live imaging methods and super-resolution techniques will surely 671 
aid in providing further understanding of the processes of extracellular vesicle 672 
uptake and their intracellular fates.  673 
 674 
[H3] Signals delivered by extracellular vesicles to recipient cells.  675 
Once docked at the plasma membrane, extracellular vesicles can elicit 676 
functional responses by binding to and activating receptors expressed on the 677 
recipient cells (Fig 5). First examples were B cells and dendritic cells derived 678 
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exosomes that were able to present antigen to T cells and induce specific 679 
antigenic response15,16. Tumour derived microvesicles were shown to carry 680 
fibronectin, which when bound to integrin on non-transformed fibroblasts was 681 
able to promote their anchorage independent growth (one of the hallmarks of 682 
tumorigenesis), contributing to the acquisition of transformed phenotype by 683 
healthy cells163. As another example, microvesicles generated and released 684 
by embryonic stem cells were shown to induce invasion of maternal tissue by 685 
the trophoblast, which is mediated by the interaction of laminin and fibronectin 686 
on the microvesicles with integrins along the surfaces of the trophoblast, and 687 
which promotes embryo implantation164. The role of extracellular vesicles in 688 
the long-range transfer of morphogens to recipient cells in developing 689 
organisms was also shown165. 690 
 691 
Cargo delivered by extracellular vesicles can also activate various responses 692 
and processes in the recipient cell after internalization. For example, in 693 
dendritic cells, protein cargo of exosomes derived from intestinal epithelial 694 
cells136 or other dendritic cells140 is processed in the endocytic compartment 695 
similarly to antigens and then used in antigen presentation, thereby 696 
contributing to immune response regulation. Extracellular vesicles could also 697 
fuse directly with the plasma membrane or with the endocytic membrane of 698 
recipients cells. Such processes are mandatory to release intraluminal content 699 
in the cytoplasm of recipient cells, a key step to support the release of 700 
miRNA62 and mRNA166 from extracellular vesicles into recipient cells to 701 
regulate gene expression. Direct fusion of extracellular vesicles with the 702 
membrane of recipients cells allow also the exchange of transmembrane 703 
proteins and lipids. Extracellular vesicles can transport various lipid species 704 
including eicosanoids, fatty acids, and cholesterol as well as lipid 705 
translocases, thereby contributing to the regulation of bioactive lipid 706 
species167. Under pathological situations, a good example of material 707 
transferred through extracellular vesicles is given by pathological amyloid 708 
proteins, which can be either enriched at the surface of extracellular vesicles 709 
such as prion protein or amyloid beta peptide, or present intraluminaly such 710 
as TDP43 and alpha-synuclein. Their transfer to recipient cells, requiring back 711 
fusion, has been proposed to favour transcellular spreading of amyloids168. 712 
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Mechanisms governing fusion of extracellular vesicles with these different 713 
compartments are not known yet, but could be analogous to fusogenic 714 
processes employed by viruses169.  715 
 716 
The ultimate and likely most frequent fate of extracellular vesicles is their 717 
targeting to lysosomes, which leads to the degradation of proteins and lipids 718 
carried by extracellular vesicles. Of importance this degradative pathway 719 
would provide a relevant source of metabolites to the recipient cells170 (Fig 5). 720 
 721 
[H1] Conclusions and perspectives 722 
Much progress has been made in recent years in understanding the basic 723 
biology of extracellular vesicles, but further investigations are required to fully 724 
resolve the functional capabilities of these vesicles. Extracellular vesicles are 725 
involved in several physiological contexts and pathological states, including 726 
blood coagulation, inflammation, stem cell expansion, neuronal 727 
communication and tumorigenesis among others6. In this context, extracellular 728 
vesicles have been shown to carry, for example, tumour-associated 729 
molecules in case of cancer and premetastatic niche establishment139 171, or 730 
particular components associated with neudegenerative diseases172. Thus, 731 
extracellular vesicles hold a great potential for clinical application. 732 
 733 
 Regulatory pathways involved in biogenesis and secretion of extracellular 734 
vesicles, when well defined, could be used to manipulate extracellular vesicle 735 
generation in pathological states, such as tumorigenesis, where the 736 
involvement of extracellular vesicles in pathology has been particularly well 737 
documented163. Nevertheless, it should be noted that manipulation of 738 
machineries involved in the biogenesis, transport or targeting of extracellular 739 
vesicles for therapeutic benefit should be approached with caution, owing to 740 
potential secondary effects of such manipulations on healthy tissues173. 741 
 742 
The broad and increasing interest in extracellular vesicles has also opened up 743 
the possibility to use exosomes and microvesicles as biomarkers to follow 744 
progression of various pathological states, for example for assessing risk of 745 
tumour progression and metastasis or for providing early biomarker of 746 
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neurodegenerative diseases172. Investigations in this area have flourished, 747 
aiming to put on solid ground the use of extracellular vesicles as biomarkers 748 
in a variety of diseases. Developing techniques to enrich for disease-749 
associated (for example, tumour-derived) extracellular vesicles to define their 750 
selective cargo can improve the sensitivity of such biomarkers174. Whether 751 
these “membrane biomarkers” correspond to endosomal-derived exosomes or 752 
membrane-derived microvesicles is so far unclear although potentially 753 
informative. Future studies and optimized isolation procedures (Box 1) will 754 
shed light on the nature of the different extracellular vesicle subpopulations 755 
that could be associated with distinct pathological states and stages of 756 
progression of a given disease.  757 
 758 
Another emerging application is the use of microvesicles and exosomes as 759 
vectors for the delivery of defined compounds or more generally for 760 
modulation of cell functions in an in vivo context. Extracellular vesicles are 761 
biocompatible, can be immunologically inert, and can, if necessary, be 762 
patient-derived and therefore with lower propensity to trigger innate and 763 
adaptive immune responses 175. Their use in clinical research have already 764 
demonstrated that extracellular vesicles secreted by immune cells (dendritic 765 
cells) stimulate the immune system and can therefore be exploited as anti-766 
tumor vaccines176,177. Several clinical trials involving the use of extracellular 767 
vesicle-based delivery are ongoing, for example for the treatment of lung 768 
cancer and melanoma, that may become part of an immunotherapy approach 769 
that has great potential for patients with advanced cancers178. Given that 770 
extracellular vesicles (in particular  exosomes) can be either 771 
immunostimulatory or  tolerogenic (immunologically inert), there are several 772 
examples of possible therapeutical interventions where extracellular vesicles 773 
can be used (reviewed in detail elsewhere5,179,172). Beside the aforementioned 774 
use of extracellular vesicles in antitumoral therapy, dendritic cells pulsed with 775 
Toxoplasma gondii release extracellular vesicles that confer protection 776 
against subsequent toxoplasma infection180. Such strategy could be 777 
considered for fungi, bacteria, parasitic protozoa and helminths172. 778 
Mesenchymal stem cells-dreived extracellular vesicles are now tested in 779 
animal models to treat acute kidney failure181, myocardial infarction182 or 780 
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ischemia183. Other undergoing assays are based on in vitro manipulation of 781 
extracellular vesicles with the loading of a particular cargo (for example 782 
interfering RNAs; suicide mRNA/protein [G] , miRNAs, drugs) to then deliver it 783 
to the target cell as a drug or for bioengineering purposes184,185. Modulating 784 
the specificity of targeting extracellular vesicles to recipient cells will be key for 785 
their use as high precision vehicles, and such approaches have already been 786 
tested to optimize the delivery of siRNAs to the brain184. 787 
 788 
Despite the enormous therapeutical potential, the field is still in demand of 789 
new in vivo models combined with powerful imaging methods to track at the 790 
single vesicle scale, the release, trafficking routes and fates of extracellular 791 
vesicles within the complex architecture of the organism (see also Box 1). Cell 792 
biologists and physicians working side by side in a complementary manner 793 
will certainly shed further light on the basic functions of extracellular vesicles 794 
and on their translation from the bench to bedside.  795 
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Box 1 1353 
Methods of isolation and analysis of extracellular vesicles. 1354 
 1355 
The release of extracellular vesicles in the extracellular space allows their 1356 
recovery from cell culture supernatants and liquid biopsies. Isolation 1357 
procedures include differential ultracentrifugation, flotation on density 1358 
gradient, separation by size exclusion chromatography, poly(ethylene glycol) 1359 
(PEG) precipitation, immunoprecipitation and commercial kits that are partly 1360 
based on these methods. These steps allow to concentrate and to separate 1361 
extracellular vesicles from protein aggregates, lipoparticles, viruses, and cell 1362 
debris with different rates of success. Combination of different isolation 1363 
procedures is encouraged to notably separate subpopulations of vesicles 1364 
based on their size, density or composition.  1365 
 1366 
Several analytical methods are available and should be combined to first 1367 
assess purity, integrity and concentration of extracellular vesicles before 1368 
further analysis or other experiments. The most commonly used approaches 1369 
for the analysis of the composition and morphology of extracellular vesicle 1370 
populations include western-blot analysis, nano-particle tracking, transmission 1371 
electron microscopy and flow cytometry and can be completed by proteomics, 1372 
lipidomics and RNA and/or DNA sequencing67,186. Functional analysis of 1373 
extracellular vesicles depends on the question to be addressed. It should 1374 
always be performed after assessment of the purity of the extracellular vesicle 1375 
pellet, as soluble proteins such as cytokines, protein complexes and 1376 
aggregates or lipoparticles are a major source of false positive results in 1377 
functional assays.  1378 
 1379 
A crowdsourcing knowledgebase (http://evtrack.org) that centralizes 1380 
extracellular vesicle studies and methodologies provide a means to 1381 
standardize extracellular vesicle research to strengthen reproducibility 1382 
between studies187. Emerging strategies are now developed to investigate 1383 
biogenesis, uptake of extracellular vesicles and the transfer of material to 1384 
recipient cells in vitro and in vivo. These strategies are mainly based on the 1385 
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labelling of isolated extracellular vesicles with fluorescent dyes or expression 1386 
of fluorescent reporters that are targeted to these vesicles. Such labelling has 1387 
some limitations188 but allows the tracking of extracellular vesicle by live cell 1388 
imaging in cell lines and, to limited extent, also in vivo189. The main limitation 1389 
being the size of the vesicles, super-resolution microscopy is one option to 1390 
assess vesicle budding at the plasma membrane or in multivesicular 1391 
endosomes, and to track their fate in recipient cells. A second approach is 1392 
based on the loading of extracellular vesicles with molecules (mRNA, micro 1393 
RNA, Cre recombinase)190,191 which induce detectable signals such as 1394 
modulation of expression of a reporter gene once released in recipient cells. 1395 
Alternative approach using optical tweezers allows the manipulation and the 1396 
visualization of single vesicle at the surface of recipient cells157. But, so far, 1397 
the field is still in demand of in vivo models that would allow reproducible 1398 
tracking of extracellular vesicles at a single vesicle and high spatio-temporal 1399 
resolution at different stages: through their biogenesis and transit routes in 1400 
secreting cells to their delivery and fate in the recipient cells. Such approach 1401 
would overcome the actual limitations linked to, for example, the biased 1402 
recovery of extracellular vesicles from the supernatant (resulting from 1403 
processes such as vesicle tethering to the membrane of the producing cell or 1404 
their re-uptake)95,124. But as in any novel field of research, pre-analytical and 1405 
analytical methods for studying extracellular vesicles are bound to evolve and 1406 
to be better standardized to render the increasing numbers of publications in 1407 
this field comparable. 1408 
 1409 
Figure Legends 1410 
Figure 1: Main features of extracellular vesicles.  1411 
(a) Extracellular vesicles comprise a heterogeneous population of membrane 1412 
vesicles of various origins. Their size may vary (typically between 50 to 500 1413 
nm but they can be even larger measuring 1-10 um). Through the last two 1414 
decades, extracellular vesicle have been denominated according to their 1415 
origin (cell type), size, morphology and cargo content but can now be 1416 
classified into two distinct classes: exosomes and microvesicles. (b) 1417 
Extracellular vesicles are formed either by budding of the plasma membrane, 1418 
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and are referred to as microvesicles or as intraluminal vesicles (ILVs) within 1419 
the lumen of multivesicular endosomes (MVEs). MVEs fuse with the plasma 1420 
membrane to release ILVs that are then called exosomes. (c) Processing of 1421 
extracellular vesicles for observation by conventional transmission electron 1422 
microscopy (TEM) causes their shrinking leading to an artefactual cup-shaped 1423 
morphology (top panel). But when observed in close to native state by cryo 1424 
electron microscopy (cryo-EM) they appear as round shaped double-leaflet-1425 
membrane enclosed structures (bottom panel). (d) Study of extracellular 1426 
vesicle composition revealed that they can carry versatile cargoes, including 1427 
proteins, lipid and nucleic acids and this content can largely vary between 1428 
cells and conditions. The particular composition will directly affect the fate and 1429 
function of extracellular vesicles, strengthening the importance of selective 1430 
cargo sorting mechanisms. Of note, according to the cell type extracellular 1431 
vesicles will display a set of cell type specific proteins that account for their 1432 
specific fates and functions. Despite a different mode of biogenesis, 1433 
exosomes and microvesicles display similar appearance, overlapping size 1434 
and often common composition that make it difficult to ascertain their origin 1435 
once isolated from the extracellular medium or from biological fluids. ARMMS, 1436 
arrestin domain-containing protein 1-mediated microvesicles; GAPDH, 1437 
glyceraldehyde-3-phosphate dehydrogenase; HSP, heat shock protein; ICAM, 1438 
intercellular adhesion molecule; TSPAN: tetraspanin; LBPA: lyso-bis-1439 
phosphatidyl acid, ICAM: InterCellular Adhesion Molecule, MHC major 1440 
histocompatibility Complex, APP: amyloid precursor protein, PMEL: 1441 
premelanosomal protein, TCR: T cell receptor, HSPG heparan sulfate 1442 
proteoglycan, CXCR4: C-X-C chemokine receptor type 4, PrP, Prion Protein, 1443 
TfR: transferrin receptor, ALIX: ALG-2 interacting protein X, Tsg101 Tumor 1444 
suppressing gene 101, vps: vacuolar protein sorting, LFA-1: Lymphocyte 1445 
function associated antigen 1., TDP43: TAR binding protein 43, GAPDH: 1446 
glyceraldehyde-3-phosphate dehydrogenase, ERK: Extracellular signal-1447 
regulated kinases, PLD: Phospholipase D. Images in part c are the courtesy 1448 
of Roberta Palmulli (G. Raposo’ laboratory, URM144, Institut Curie) for 1449 
conventional TEM and of Daniel Levy (UMR168, Institut Curie). 1450 
 1451 
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Figure 2: Biogenesis of extracellular vesicles  1452 
Several sorting machineries are involved in the different steps required for 1453 
exosomes and microvesicles generation. First, lipids and membrane-1454 
associated proteins are clustered in discrete membrane microdomains of the 1455 
plasma membrane for microvesicles (top) and the limiting membrane of the 1456 
multivesicular endosome (MVE) for exosomes (bottom) (step 1). Such 1457 
microdomains certainly also participate in the recruitment of soluble 1458 
components fated for sorting in extracellular vesicles such as cytosolic 1459 
proteins and RNA species (step 2). Altogether formation of these clustered 1460 
microdomains together with additional machineries promote membrane 1461 
budding followed by a fission process either at the plasma membrane towards 1462 
the extracellular medium or at the limiting membrane of the MVE towards the 1463 
lumen of MVE (step 3). Transmembrane proteins sorted on exosomes and 1464 
microvesicles keep the same topology as at the plasma membrane. 1465 
Mechanisms of exosome biogenesis are relatively well understood and 1466 
importantly involve subunits of endosomal sorting complex required for 1467 
transport (ESCRT), although to a different degree — ESCRT-III is required for 1468 
the scission of the intraluminal vesicles (ILVs) into the MVE lumen, but 1469 
membrane budding can occur by either ESCRT-dependent or ESCRT-1470 
independent mechanisms. The mechanisms involved in the biogenesis of 1471 
microvesicles is still expanding. Notably, the molecular machineries that act at 1472 
the different steps of extracellular vesicle biogenesis are at least partly 1473 
common to exosomes and microvesicles (prominently including ESCRT 1474 
proteins but also generation of ceramide through the action of different types 1475 
of sphingomyelinase). One exception is the flipping of specific lipid species 1476 
between the leaflets of the budding membrane that has been uniquely 1477 
reported so far to microvesicle budding. Thus, it is difficult to ascertain the 1478 
origin of the produced extracellular vesicle by simply impairing the function of 1479 
a given mechanism involved in biogenesis of these vesicles. ARF6, ADP-1480 
ribosylation factor 6. 1481 
 1482 
Figure 3: Origin of exosome diversity in relation to sorting machineries.  1483 
The diversity of extracellular vesicle sub-populations with distinct composition 1484 
and function that are generated by a given cell type is often attributed to the 1485 
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production of distinct sets of exosomes and microvesicles23,192. This diversity 1486 
is well-exemplified by the secretion of different exosomes sub-populations — 1487 
with distinct morphology and composition — from apical and basolateral sides 1488 
of polarized cells such as intestinal epithelial cells193 194 195. Such exosome 1489 
sub-populations are likely originating from sub-populations of MVEs. The 1490 
distinct composition of these subpopulations reflects on the presence of 1491 
multiple sorting machineries that act on the MVE compartment. It remains to 1492 
be determined whether the different sorting machineries act on distinct sub-1493 
populations of MVEs (see part on right) or concomitantly in single MVEs to 1494 
generate distinct sub-populations of intraluminal vesicles (ILVs) (see part on 1495 
the left). The reality is most likely a mix of these two possibilities, with distinct 1496 
contribution depending on the cell type. Recruitment of a given sorting 1497 
machinery can depend on the maturation stage of the producing cells52 74, on 1498 
the post-translational modification of the cargo (for example: proteolytic 1499 
processing, ubiquitylation) 49,193 or potentially on the stage of maturation of 1500 
MVEs. The type of sorting machinery recruited to MVEs will also specify the 1501 
fate of MVEs between exosome secretion and lysosomal degradation. 1502 
ESCRT, endosomal sorting complex required for transport. 1503 
 1504 
Figure 4: Interdependency of intracellular trafficking routes in the generation 1505 
of extracellular vesicles 1506 
The generation of exosomes and microvesicles requires a tuned regulation of 1507 
multiple intracellular trafficking steps (blue arrows for exosomes, green arrows 1508 
for microvesicles) that influence the targeting of cargoes to the site of 1509 
extracellular vesicle biogenesis as well as for exosomes, the fate of the 1510 
multivesicular endosome (MVE) from which these vesicles originate. Cargoes 1511 
targeted to MVEs originate from endocytosis at the plasma membrane or are 1512 
directly targeted to MVEs or to early sorting endosomes via the biosynthetic 1513 
pathway (from the trans-Golgi Network (TGN)). Retrograde transport towards 1514 
the TGN or recycling back to the plasma membrane will divert cargoes from 1515 
their targeting to MVE (dashed arrows) and therefore their incorporation into 1516 
ILVs. These sorting processes are regulated by various Rab GTPases. Once 1517 
matured, MVEs that are not targeted to lysosomes or autophagosomes for 1518 
degradation are transported to the plasma membrane on microtubules. At this 1519 
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step, docking and fusion are the two final processes required for exosome 1520 
release. Rabs, actin and soluble N-ethylmaleimide-sensitive factor attachment 1521 
protein receptor (SNARE) proteins are involved in these steps of exosome 1522 
release. In the case of microvesicle biogenesis, endocytic uptake (dashed 1523 
arrow) and recycling will respectively decrease and increase the targeting of 1524 
membrane (and membrane bound) cargoes to microvesicles. Of note, as the 1525 
release of exosomes requires tightly regulated steps of transport, tethering 1526 
and fusion of MVE to plasma membrane (apart from cargo sorting) this could 1527 
account for the time difference between the generation and release of both 1528 
types of extracellular vesicles. OK * denotes proteins of Caenorhabditis 1529 
elegans.  1530 
 1531 
 1532 
Figure 5: Fate of extracellular vesicles in recipient cells.  1533 
In recipient cell (which can be the producing cell itself) exogenous 1534 
extracellular vesicles will bind to the cell surface (see inset) and can follow 1535 
various fates. Depending on the cell type they can remain bound to the 1536 
surface (for example to integrins) and can initiate intracellular signalling 1537 
pathways (for example antigen presentation). Extracellular vesicles may also 1538 
be internalized by multiple routes. Internalization will target exogenous 1539 
extracellular vesicles into the canonical endosomal pathway, whereby they 1540 
reach multivesicular endosomes (MVEs) where the uptaken vesicles will likely 1541 
mix with endogenous intraluminal vesicles (ILVs). Fusion of MVEs with the 1542 
lysosome will lead to the degradation of extracellular vesicles and the 1543 
recycling of their content to fuel recipient cell metabolism. Extracellular 1544 
vesicles either docked at the plasma membrane or at the limiting membrane 1545 
of MVEs can release their intraluminal content into the cytoplasm of the 1546 
recipient cell by fusion, a process which is so far poorly understood but of 1547 
major importance for delivery of intraluminal cargoes such as miRNA. Of note, 1548 
there is no evidence so far to exclude potential recycling to the plasma 1549 
membrane of endocytosed vesicles (dashed arrows). ECM, extracellular 1550 
matrix; ICAM, intercellular adhesion molecules; TIM4, T-cell immunoglobulin 1551 
mucin receptor 4.  1552 
 1553 
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 1554 
Glossary  1555 
reticulocytes: precursors of red blood cells (erythrocytes) 1556 
 1557 
sorting machineries: protein complexes mediating cargo sorting in 1558 
endosomes 1559 
 1560 
major histocompatibility complex: a group of genes that code for cell-1561 
surface glycoproteins that help the immune system to determine self and 1562 
nonself  1563 
 1564 
syntenin: an intracellular adaptor protein linking syndecan-mediated 1565 
signalling to the cytoskeleton 1566 
 1567 
syndecan: a single transmembrane domain heparan sulfate proteoglycan that 1568 
binds a large variety of ligands, such as growth factors and fibronectin among 1569 
others 1570 
 1571 
ceramide: a lipid molecule composed of sphingosine and a fatty acid linked 1572 
through an amide bound; in fact, many chemically diverse ceramides have 1573 
been described, showing that ceramide is not a single molecular species but 1574 
rather a family of related molecules.  1575 
 1576 
sphingomyelin: a type of sphingolipid found in animal cell membranes.  1577 
 1578 
tetraspanin family: family of proteins with four transmembrane domains 1579 
which allow association with other members of the family and with other 1580 
proteins to generate dynamic membrane domains.  1581 
 1582 
GlycosylPhosphatidyInostol (GPI)-anchored proteins: a posttranslational 1583 
modification, comprising a phosphoethanolamine linker, glycan core, and 1584 
phospholipid tail, that anchors the modified protein to the outer leaflet of the 1585 
cell membrane. 1586 
 1587 
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lipid rafts: specialized membrane microdomains enriched in cholesterol and 1588 
glycosphingolipid which serve as organizing centers for the assembly of 1589 
signalling molecules.  1590 
 1591 
KRAS–MEK signalling pathway: interaction between the proto-oncogene 1592 
KRAS which encodes a small GTPase and the downstream effector, the 1593 
canonical RAF–MEK–EERK signalling pathway. Both pathways have roles in 1594 
cell division, cell differentiation and apoptosis. 1595 
 1596 
Major Vault protein: the main component of ribonucleoparticles termed 1597 
vaults, which also contains two additional proteins, the vault poly (ADP-ribose) 1598 
polymerase (vPARP) and the telomerase-associated protein 1 (TEP1), and 1599 
several short untranslated, vault RNAs (vRNA). It has been implicated in the 1600 
regulation of several cellular processes including transport mechanisms, 1601 
signal transmissions and immune responses.  1602 
 1603 
Y-box protein 1: a transcription factor shown to have a role in oncogenic cell 1604 
transformation, multiple drug resistance and dissemination of tumours. 1605 
aminophospholipid translocases: enzymes which transport 1606 
phosphatidylserine and phosphatidylethanolamine from one side of a bilayer 1607 
to another. 1608 
scramblases: proteins responsible for the translocation of phospholipids 1609 
between the inner and outer leaflet of a cell membrane. 1610 
calpain: a calcium-dependent protein expressed ubiquitously in mammals 1611 
and many other organisms. 1612 
  1613 
Rho family of small GTPases: a family of small signalling G proteins 1614 
implicated in the regulation of many aspects of actin dynamics. 1615 
 1616 
brush border: the microvilli-covered surface of epithelial cells found in 1617 
enterocytes in the intestine.  1618 
 1619 
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Warburg effect: an aerobic process whereby cancer cells produce energy by 1620 
a high rate of glycolysis followed by lactic acid fermentation in the cytosol, 1621 
rather than by oxidation of pyruvate in mitochondria 1622 
 1623 
zipcode RNA sequence motifs: cis-acting regulatory sequences (25 1624 
nucleotides) in the 3′-untranslated region (3′UTR) of mRNA transcripts that 1625 
mediate binding of a ribonuclear protein complex to the mRNA, thereby 1626 
temporarily blocking mRNA translation and that mediate movement of mRNA 1627 
via the cytoskeleton to a cellular location where mRNA is released from 1628 
protein binding and translation initiates. 1629 
 1630 
immunological synapse: a specialized cell–cell junction between a thymus-1631 
derived lymphocyte (T cell) and an antigen-presenting cell. 1632 
 1633 
Hedgehog: an essential signalling molecule, termed morphogen, required for 1634 
numerous processes during animal development. 1635 
 1636 
ISGylation: an ubiquitin-like modification that controls exosome release by 1637 
decreasing the number of multivesicular endosomes. 1638 
 1639 
caveolin: the principal component of caveolae, which are involved in receptor 1640 
(clathrin)-independent endocytosis, mechanotransduction and lipid 1641 
homeostasis.OK 1642 
 1643 
 1644 
SNARE proteins: an acronym derived from "SNAP (Soluble NSF Attachment 1645 
Protein) REceptor"); their primary role is to mediate the fusion of intracellular 1646 
vesicles with their target membrane bound compartments.  1647 
 1648 
Synaptotagmin family: family of membrane-trafficking proteins that has been 1649 
implicated in calcium- dependent neurotransmitter release. 1650 
 1651 
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Protein kinase C: a serine/threonine kinase which plays important roles in 1652 
several signal transduction cascades by controlling the function of other 1653 
proteins through their phosphorylation.  1654 
 1655 
P2x7 receptors: trimeric ATP-gated cation channels found predominantly, but 1656 
not exclusively, on immune cells, which have been implicated in various 1657 
inflammatory, immune, neurologic and musculoskeletal disorders. 1658 
 1659 
follicular dendritic cells: cells of the immune system found in primary and 1660 
secondary lymph follicles of the B cell areas of the lymphoid tissue. 1661 
 1662 
lectin: a carbohydrate-binding protein that is highly specific for sugar 1663 
moieties.  1664 
 1665 
proteoglycans: heavily glycosylated proteins consisting of a “core protein” 1666 
with one or more covalently attached glycosaminoglycans (GAG) chains 1667 
 1668 
Intercellular adhesion molecules (ICAMs): member of the immunoglobulin 1669 
superfamily, which are involved in inflammation, immune responses and in 1670 
intracellular signalling events.  1671 
 1672 
macropinocytosis a form of regulated endocytosis that involves the non-1673 
specific uptake of extracellular material (such as small soluble molecules, 1674 
nutrients, antigens) by invagination of the plasma membrane, which is then 1675 
pinched resulting in small vesicles in the cytoplasm. 1676 
 1677 
trophoblast: cells which form the outer layer of a blastocyst, provide nutrients 1678 
to the embryo and give rise to a large part of the placenta. 1679 
 1680 
microglia: a type of brain glial cell acting as the first and main endogenous 1681 
immune defense in the central nervous system  1682 
 1683 
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astrocytes: star-shaped glial cells in the brain involved in nutrient supply, 1684 
maintenance of extracellular ion balance and in tissue repair following brain 1685 
injuries  1686 
 1687 
filopodia: highly dynamic actin-rich cell-surface protrusions used by cells to 1688 
sense their external environment.  1689 
 1690 
suicide mRNA/protein: suicide gene which encodes nonmammalian 1691 
enzymes that convert an inactive drug into highly toxic metabolites that inhibit 1692 
the synthesis of nucleic acids and causes cells to go to apotosis 1693 
 1694 
 1695 
 1696 
 1697 
Key points  1698 
 Secretion of extracellular vesicles was initially described as means of 1699 
selective elimination of proteins, lipids and RNA from the cells. Now, 1700 
extracellular vesicles are also considered as a new mode of 1701 
intercellular communication. 1702 
 In any given setting, population of extracellular vesicles comprises 1703 
diverse subpopulations that can differ in size, morphology, composition 1704 
or biogenesis mechanisms. Complementary methods of analysis are 1705 
required to distinguish between these subpopulations.  1706 
 Several machineries, prominently including components of the 1707 
endocytic sorting machineries, act concomitantly for the generation of 1708 
extracellular vesicles. In result, extracellular vesicles can largely vary in 1709 
terms of their composition and may carry specific sets of proteins, 1710 
lipids, RNA species that then determine their fate and functions. 1711 
 Generation of extracellular vesicles requires a fine tuning of various 1712 
intracellular trafficking processes, which define the composition of 1713 
nascent vesicles and impact their generation and, in the case of 1714 
exosomes, their secretion from an intracellular compartment.  1715 
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 Interactions of extracellular vesicles with recipient cells and their can 1716 
have various effects on the target cell, from stimulating signalling 1717 
pathways to providing trophic support, which depends on the mode of 1718 
interaction and the intracellular fate of the vesicles in case of their 1719 
uptake.  1720 
 Studies of the cell biology of extracellular vesicles is not only essential 1721 
for addressing cell biological questions but is also critical to open new 1722 
avenues for their clinical use as biomarkers, cargo vehicles for targeted 1723 
delivery of compounds or as specific modulators of cell behaviours.  1724 
 1725 
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